Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast

Carmine Valenza1, Ann H Partridge1, Meredith M Regan2

  • 1Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.

Abstract

No abstract available in PubMed .